Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Engineered to specifically act on the vascular endothelial growth factor receptor 2 (VEGFR2), BR55 (perfluorobutane/nitrogen ...

Maternal vitamin D status in early pregnancy is crucial for fetal growth and may reduce the risk of preterm birth, according ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Opthea Limited (NASDAQ:OPT – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $5.49, but opened at $5.68. Opthea shares last traded at $5.65, with a ...

ONS-5010 (bevacizumab-vikg) was found to be noninferior to ranibizumab for neovascular age-related macular degeneration at week 12.

If you want to learn to paint, you might take a class and spend time practicing and honing your skills. Even though your first painting might not be all that you hoped for, you feel if you keep ...

By binding to specific receptors on target cells, they deliver ‘instructions’ that can prompt those cells to carry out specific functions,” Dr. Khalifian explains. “These messenger ...

Leerink Partners analyst Marc Goodman has maintained their bullish stance on OPT stock, giving a Buy rating yesterday.Invest with Confidence: ...